Data News > Regeneron Pharmaceuticals, Inc. Faces Class Action Lawsuit for Securities Fraud
- Class action lawsuits have been filed against Regeneron Pharmaceuticals, Inc. for violations of federal securities laws.
- Investors who suffered losses between November 2, 2023, and October 30, 2024, have until March 10, 2025, to seek potential recovery.
- Multiple law firms are encouraging investors with substantial losses to join the class action lawsuit against Regeneron.
- Shares of Regeneron plunged, resulting in billions of dollars in losses for investors following the Q3 2024 earnings report.
- The Schall Law Firm and other legal entities are urging shareholders to come forward and seek potential damages.
Regeneron Pharmaceuticals, Inc. is currently facing a class action lawsuit for securities fraud, with multiple law firms reaching out to investors who suffered losses on their investments in the company. The lawsuits stem from alleged violations of federal securities laws by Regeneron and certain senior executives during the period between November 2, 2023, and October 30, 2024.
Investors who purchased or acquired Regeneron common stock during this Class Period have until March 10, 2025, to file a lead plaintiff motion and potentially seek recovery. The law firms involved in these cases, including Levi & Korsinsky, DiCello Levitt LLP, Law Offices of Howard G. Smith, and The Schall Law Firm, are actively encouraging affected investors to discuss their options with legal counsel.
One of the key events that triggered these legal actions was the substantial losses incurred by investors following the Q3 2024 earnings report, where shares of Regeneron plummeted, resulting in a loss of approximately $9 billion in market value. Hagens Berman has initiated an investigation to determine whether investors were misled about the company's marketing and reimbursement practices related to its EYLEA product.
The Schall Law Firm, along with other legal entities such as Levi & Korsinsky and Bronstein, Gewirtz & Grossman LLC, are urging shareholders with substantial losses to come forward and potentially lead the class action lawsuit against Regeneron Pharmaceuticals, Inc. Investors who purchased the company's securities during the specified Class Period are advised to contact the respective law firms before the March 10, 2025, deadline to explore their legal rights and options.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Regeneron Pharmaceuticals, Inc. Faces Class Action Lawsuit for Securities Fraud
By KlickAnalytics Data Insights | January 10, 2025 08:00PM ET
Key Points
- Class action lawsuits have been filed against Regeneron Pharmaceuticals, Inc. for violations of federal securities laws.
- Investors who suffered losses between November 2, 2023, and October 30, 2024, have until March 10, 2025, to seek potential recovery.
- Multiple law firms are encouraging investors with substantial losses to join the class action lawsuit against Regeneron.
- Shares of Regeneron plunged, resulting in billions of dollars in losses for investors following the Q3 2024 earnings report.
- The Schall Law Firm and other legal entities are urging shareholders to come forward and seek potential damages.
Regeneron Pharmaceuticals, Inc. is currently facing a class action lawsuit for securities fraud, with multiple law firms reaching out to investors who suffered losses on their investments in the company. The lawsuits stem from alleged violations of federal securities laws by Regeneron and certain senior executives during the period between November 2, 2023, and October 30, 2024.
Investors who purchased or acquired Regeneron common stock during this Class Period have until March 10, 2025, to file a lead plaintiff motion and potentially seek recovery. The law firms involved in these cases, including Levi & Korsinsky, DiCello Levitt LLP, Law Offices of Howard G. Smith, and The Schall Law Firm, are actively encouraging affected investors to discuss their options with legal counsel.
One of the key events that triggered these legal actions was the substantial losses incurred by investors following the Q3 2024 earnings report, where shares of Regeneron plummeted, resulting in a loss of approximately $9 billion in market value. Hagens Berman has initiated an investigation to determine whether investors were misled about the company's marketing and reimbursement practices related to its EYLEA product.
The Schall Law Firm, along with other legal entities such as Levi & Korsinsky and Bronstein, Gewirtz & Grossman LLC, are urging shareholders with substantial losses to come forward and potentially lead the class action lawsuit against Regeneron Pharmaceuticals, Inc. Investors who purchased the company's securities during the specified Class Period are advised to contact the respective law firms before the March 10, 2025, deadline to explore their legal rights and options.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.